Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys

Psychoneuroendocrinology

Volumn 33, Issue 4, 2008, Pages 478-486

  Pascoe, John E ^a   Williams, Keith L ^b   Mukhopadhyay, Partha ^a   Rice, Kenner C ^c   Woods, James H ^a   Ko, Mei Chuan ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

ACTH; Cortisol; HPA axis; Opioid receptor agonists; Opioid receptor antagonists; Primates

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; CORTICOTROPIN; DELTA OPIATE RECEPTOR AGONIST; FENTANYL; HYDROCORTISONE; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; NORBINALTORPHIMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DOSE RESPONSE; FEMALE; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHESUS MONKEY;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ADRENOCORTICOTROPIC HORMONE; ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MACACA MULATTA; MALE; PIPERAZINES; PITUITARY-ADRENAL SYSTEM; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 41849151395     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.01.006     Document Type: Article

References (48)

1. Bowen C.A., Negus S.S., Kelly M., and Mello N.K. The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative-dosing procedures. Psychoneuroendocrinology 27 (2002) 319-336
2. Brandt M.R., Furness M.S., Mello N.K., Rice K.C., and Negus S.S. Antinociceptive effects of δ-opioid agonists in rhesus monkeys: effects on chemically induced thermal hypersensitivity. J. Pharmacol. Exp. Ther. 296 (2001) 939-946
3. Broadbear J.H., Winger G., Cicero T.J., and Woods J.H. Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. J. Pharmacol. Exp. Ther. 289 (1999) 1641-1647
4. Broadbear J.H., Winger G., and Woods J.H. Self-administration of fentanyl, cocaine, and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology 176 (2004) 398-406
5. Buckingham J.C., and Cooper T.A. Pharmacological characterization of opioid receptors influencing the secretion of corticotrophin releasing factor in the rat. Neuroendocrinology 44 (1986) 36-40
6. Butelman E.R., Negus S.S., Ai Y., de Costa B.R., and Woods J.H. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 267 (1993) 1269-1276
7. Butelman E.R., Ko M.C., Sobczyk-Kojiro K., Mosberg H.I., Van Bemmel B., Zernig G., and Woods J.H. Kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J. Pharmacol. Exp. Ther. 285 (1998) 595-601
8. Butelman E.R., Harris T.J., Perez A., and Kreek M.J. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys. J. Pharmacol. Exp. Ther. 290 (1999) 678-686
9. Butelman E.R., Harris T.J., and Kreek M.J. Antiallodynnic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J. Pharmacol. Exp. Ther. 311 (2004) 155-163
10. Butelman E.R., Mandau M., Tidgewell K., Prisinzano T.E., Yuferov V., and Kreek M.J. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J. Pharmacol. Exp. Ther. 320 (2007) 300-306
11. Cowan A., Lewis J.W., and MacFarlane I. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60 (1977) 537-545
12. Degli Uberti E.C., Salvadori S., Trasforini G., Margutti A., Ambrosio M.R., Rossi R., Portaluppi F., and Pansini R. Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotrophin-releasing hormone in healthy man. J. Clin. Endocrinol. Metab. 75 (1992) 370-374
13. Dykstra L.A., Gmerek D.E., Winger G., and Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242 (1987) 413-420
14. Endoh T., Matsuura H., Tanaka C., and Nagase H. Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch. Int. Pharmacodyn. 316 (1992) 30-42
15. Gonzalvez M.L., Milanés M.V., and Vargas M.L. Effects of acute and chronic administration of μ- and δ-opioid agonists on the hypothalamic-pituitary-adrenocortical (HPA) axis in the rat. Eur. J. Pharmacol. 200 (1991) 155-158
16. Hoehe M., Duka T., and Doenicke A. Human studies on the μ opidate receptor agonist fentanyl: neuroendocrine and behavioral responses. Psychoneuroendocrinology 13 (1988) 397-408
17. Horan P., Taylor J., Yamamura H.I., and Porreca F. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J. Pharmacol. Exp. Ther. 260 (1992) 1237-1243
18. Ignar D.M., and Kuhn C.M. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J. Pharmacol. Exp. Ther. 255 (1990) 1287-1295
19. Iyengar S., Kim H.S., and Wood P.L. Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res. 435 (1987) 220-226
20. Jackson R.V., Grice J.E., Hockings G.I., and Torpy D.J. Naloxone-induced ACTH release: mechanism of action in humans. Clin. Endocrinol. 43 (1995) 423-424
21. Jewett D.C., and Woods J.H. Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons. Behav. Pharmacol. 6 (1995) 815-820
22. Ko M.C., Butelman E.R., and Woods J.H. The role of peripheral Mu opioid receptors in the modulation of capsaicin-induced thermal nociception in rhesus monkeys. J. Pharmacol. Exp. Ther. 286 (1998) 150-156
23. Ko M.C.H., Johnson M.D., Butelman E.R., Willmont K.J., Mosberg H.I., and Woods J.H. Intracisternal nor-binaltorphimine distinguishes central and peripheral κ-opioid antinociception in rhesus monkeys. J. Pharmacol. Exp. Ther. 291 (1999) 1113-1120
24. Ko M.C., Terner J., Hursh S., Woods J.H., and Winger G. Relative reinforcing effects of three opioids with different durations of action. J. Pharmacol. Exp. Ther. 301 (2002) 698-704
25. Ko M.C.H., Willmont K.J., Lee H., Flory G.S., and Woods J.H. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res. 982 (2003) 38-44
26. Lee H., Naughton N.N., Woods J.H., and Ko M.C. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 107 (2007) 478-485
27. Martin T.J., and Eisenach J.C. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J. Pharmacol. Exp. Ther. 299 (2001) 811-817
28. McDonald R.K., Evans F.T., Weise V.K., and Patrick R.W. Effect of morphine and nalorphine on plasma hydrocortisone levels in man. J. Pharmacol. Exp. Ther. 125 (1959) 241-247
29. Mellon R.D., and Bayer B.M. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J. Neuroimmunol. 83 (1998) 19-28
30. Miller D.B., and O'Callaghan J.P. Neuroendocrine aspects of the response to stress. Metabolism 51 (2002) 5-10
31. Morley J. Neuroendocrine effects of endogenous opioid peptides in human subjects: a review. Psychoneuroendocrinology 8 (1983) 361-379
32. Naber D., Pickar D., Davis G.C., Cohen R.M., Jimerson D.C., Elchisak M.A., Defraites E.G., Kalin N.H., Risch S.C., and Buchsbaum M.S. Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA, MHPG in plasma of normal volunteers. Psychopharmacology 74 (1981) 125-128
33. Negus S.S., Gatch M.B., Mello N.K., Zhang X., and Rice K. Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J. Pharmacol. Exp. Ther. 286 (1998) 362-375
34. Nikolarakis K., Pfeiffer A., Stalla G.K., and Herz A. The role of CRF in the release of ACTH by opiate agonists and antagonists in rats. Brain Res. 421 (1987) 373-376
35. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu. Rev. Pharmacol. Toxicol. 32 (1993) 353-382
36. 33P in situ hybridization study. Neuroscience 88 (1999) 1093-1135
37. Pende A., Musso N.R., Montaldi M.L., Pastorino G., Arzese M., and Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed. Pharmacother. 40 (1986) 178-182
38. Peng P.W., and Sandler A.N. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90 (1999) 576-599
39. Rosen M.I., McMahon T.J., Hameedi F.A., Pearsall H.R., Woods S.W., Kreek M.J., and Kosten T.R. Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. J. Pharmacol. Exp. Ther. 276 (1996) 1128-1135
40. Simantov R., and Snyder S.H. Opiate receptor binding in the pituitary gland. Brain Res. 124 (1977) 178-184
41. 35S]Guanylyl-5′-O-(γ-Thio)-triphosphate binding in cynomolgus monkey brain. Neuroscience 94 (1999) 651-662
42. Ur E., Wright D.M., Bouloux P.M.G., and Grossman A. The effects of spiradoline (U-62066E), a κ-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120 (1997) 781-784
43. Volavka J., Cho D., and Mallya A. Naloxone increases ACTH and cortisol levels in man. N. Engl. J. Med. 300 (1979) 1056-1057
44. Walker E.A., Zernig G., and Woods J.H. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J. Pharmacol. Exp. Ther. 273 (1995) 1345-1352
45. Wand G.S., and Schumann H. Relationship between plasma adrenocorticotropin, hypothalamic opioid tone, and plasma leptin. J. Clin. Endocrinol. Metab. 83 (1998) 2138-2142
46. Williams K.L., Ko M.C.H., Rice K.C., and Woods J.H. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Psychoneuroendocrinology 28 (2003) 513-528
47. Winger G., Stitzer M.L., and Woods J.H. Barbiturate-reinforced responding in rhesus monkeys: comparisons of drugs with different durations of action. J. Pharmacol. Exp. Ther. 195 (1975) 505-514
48. Zis A.P., Haskett R.F., Albala A.A., and Carroll B.J. Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 9 (1984) 423-427